Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours
Clinicaltrials.gov ID
NCT05489211
Status
Recruiting
Study Type
Interventional, Phase 2
Sponsor
AstraZeneca
Start Date
Anticipated End Date
Study Contact
Name: AstraZeneca Clinical Study Information Center
Phone Number:1-877-240-9479
About the Study
TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.
Conditions
Endometrial Cancer
Gastric Cancer
Metastatic Castration-resistant Prostate Cancer
Ovarian Cancer
Colorectal Cancer
Urothelial Cancer
Biliary Tract Cancer
Inclusion/Exclusion Criteria?
Primary, Secondary, Other Outcome Measures??
Locations in Canada
Sunnybrook Hospital, Toronto, Ontario, M4N 3M5, Canada
Princess Margaret Cancer Centre, Toronto, Ontario, M5G 2M9, Canada
CHUM, Montreal, Quebec, H2X 0A9, Canada
McGill University Health Centre, Montreal, Quebec, H4A 3J1, Canada
Hôpital Enfant-Jésus, Quebec, Quebec, G1J 1Z4, Canada
About the Study
TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.
Conditions
Endometrial Cancer
Gastric Cancer
Metastatic Castration-resistant Prostate Cancer
Ovarian Cancer
Colorectal Cancer
Urothelial Cancer
Biliary Tract Cancer
Interventions
DRUG:
Datopotamab deruxtecan (Dato-DXd)
AZD5305
Durvalumab
Capecitabine
5-Fluorouracil
Volrustomig
Carboplatin
Leucovorin LV
Bevacizumab
Rilvegostomig
Prednisone/ prednisolone
Locations in Canada
Sunnybrook Hospital, Toronto, Ontario, M4N 3M5, Canada
Princess Margaret Cancer Centre, Toronto, Ontario, M5G 2M9, Canada
CHUM, Montreal, Quebec, H2X 0A9, Canada
McGill University Health Centre, Montreal, Quebec, H4A 3J1, Canada
Hôpital Enfant-Jésus, Quebec, Quebec, G1J 1Z4, Canada